Competing mortality contributes to excess mortality in patients with poor-risk lymph node-positive prostate cancer treated with radical prostatectomy

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Michael Froehner - , Universitätsklinikum Carl Gustav Carus Dresden, Klinik und Poliklinik für Urologie (Autor:in)
  • Albrecht Scholz - , Helios Klinikum Aue (Autor:in)
  • Rainer Koch - , Universitätsklinikum Carl Gustav Carus Dresden, Institut für Medizinische Informatik und Biometrie (Autor:in)
  • Oliver W. Hakenberg - , Universität Rostock (Autor:in)
  • Gustavo B. Baretton - , Institut für Pathologie, Universitätsklinikum Carl Gustav Carus Dresden (Autor:in)
  • Manfred P. Wirth - , Universitätsklinikum Carl Gustav Carus Dresden, Klinik und Poliklinik für Urologie (Autor:in)

Abstract

Background: Factors predicting survival in men with lymph node-positive prostate cancer are still poorly defined. Patients and Methods: 193 prostate cancer patients with histopathologically proven lymph node involvement with a median follow-up of 7.3 years were studied. 94% of patients received immediate hormonal therapy. Kaplan-Meier curves were calculated to evaluate overall survival rates and compared with the log-rank test. Cumulative disease-specific and competing mortality rates were calculated by competing risk analysis and compared with the Pepe-Mori test. Cox proportional hazard models were used to determine the independent significance of predictors of all-cause mortality. Results: Age (70 years or older vs. younger), Gleason score (8-10 vs. 7 or lower) and the number of involved nodes (3 or more vs. 1-2) were identified as independent predictors of all-cause mortality. When patients with 0-1 of these risk factors were compared with those with 2-3 risk factors, all-cause (rates after 10 years 21% vs. 71%, p < 0.0001), disease-specific (12 vs. 37%, p = 0.009) and competing mortality (9 vs. 33%, p = 0.02) differed significantly. Conclusions: Some of the excess mortality in patients with poor-risk lymph node-positive prostate cancer may be attributed to increased competing mortality, possibly caused by an interaction between comorbid diseases and hormonally treated persistent or progressive prostate cancer.

Details

OriginalspracheEnglisch
Seiten (von - bis)148-154
Seitenumfang7
FachzeitschriftUrologia internationalis
Jahrgang89
Ausgabenummer2
PublikationsstatusVeröffentlicht - Sept. 2012
Peer-Review-StatusJa

Externe IDs

PubMed 22813937

Schlagworte

Ziele für nachhaltige Entwicklung

ASJC Scopus Sachgebiete

Schlagwörter

  • Competing mortality, Disease-specific survival, Lymph nodes, Overall survival, Prognostic factors, Prostate cancer, Radical prostatectomy, Urological neoplasms